SG11201808354PA - Column-based fully scalable raav manufacturing process - Google Patents
Column-based fully scalable raav manufacturing processInfo
- Publication number
- SG11201808354PA SG11201808354PA SG11201808354PA SG11201808354PA SG11201808354PA SG 11201808354P A SG11201808354P A SG 11201808354PA SG 11201808354P A SG11201808354P A SG 11201808354PA SG 11201808354P A SG11201808354P A SG 11201808354PA SG 11201808354P A SG11201808354P A SG 11201808354PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- aiex
- avb
- pennsylvania
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011111001011111111001111101111011111 International Bureau ... ..... ..)d (10) International Publication Number (43) International Publication Date ..... .....::„I WO 2017/173283 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (US). WRIGHT, John Fraser; 68 River Birch Circle, A61K 38/46 (2006.01) Cl 2N 15/86 (2006.01) Princeton, New Jersey 08540 (US). (21) International Application Number: (74) Agent: BEDGOOD, Robert M.; Pillsbury Winthrop Shaw PCT/US2017/025396 Pittman LLP, P.O. Box 10500, McLean, Virginia 22102 (US). (22) International Filing Date: 31 March 2017 (31.03.2017) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, DO, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, 62/316,252 31 March 2016 (31.03.2016) US KP, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: SPARK THERAPEUTICS, INC. [US/US]; MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 3737 Market Street, Suite 1300, Philadelphia, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, Pennsylvania 19104 (US). RU, TH, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (72) Inventors: QU, Guang; 22 Beaver Dam Drive, Sick- ZA, ZM, ZW. lerville, New Jersey 08081 (US). OH, Younghoon; 107 Lowrys Lane, Bryn Mawr, Pennsylvania 19010 (US). LU, (84) Designated States (unless otherwise indicated, for every Lin; 439 Robin Hill Road, Wayne, Pennsylvania 19087 kind GM, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [Continued on next page] (54) Title: COLUMN-BASED FULLY SCALABLE RAAV MANUFACTURING PROCESS (57) : In accordance with the invention, provided FIG. 3 herein are methods for purifying recombinant adeno-associ- ated (rAAV) vector particles. All column purification process 1 2 3 4 98 62 vpl vp2 vp3 49 1. AVB 2. AVB > CIEX > AIEX Il 3. AVB AIEX > 4. CIEX > UF/DF > SEC > en ot AIEX (50-60 M ei 1 7 50-60% vector recovery IN 1-1 IN 1-1 0 ei 0 WO 2017/173283 Al MIDEDIMOMOIDEIRMEMOMMEINIMMOOMEHOIS TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, — as to the applicant's entitlement to claim the priority of TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, — the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, Published: GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — with international search report Declarations under Rule 4.17: (Art. 21(3)) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316252P | 2016-03-31 | 2016-03-31 | |
| PCT/US2017/025396 WO2017173283A1 (en) | 2016-03-31 | 2017-03-31 | Column-based fully scalable raav manufacturing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808354PA true SG11201808354PA (en) | 2018-10-30 |
Family
ID=59966426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808354PA SG11201808354PA (en) | 2016-03-31 | 2017-03-31 | Column-based fully scalable raav manufacturing process |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11702639B2 (en) |
| EP (1) | EP3436051B1 (en) |
| JP (2) | JP7364306B2 (en) |
| KR (1) | KR102405250B1 (en) |
| CN (1) | CN109152821A (en) |
| AU (1) | AU2017240721B2 (en) |
| BR (1) | BR112018070256A2 (en) |
| CA (1) | CA3019133A1 (en) |
| CL (1) | CL2018002754A1 (en) |
| CO (1) | CO2018011151A2 (en) |
| DK (1) | DK3436051T3 (en) |
| ES (1) | ES2896080T3 (en) |
| HU (1) | HUE056854T2 (en) |
| IL (1) | IL261970A (en) |
| LT (1) | LT3436051T (en) |
| MY (1) | MY195391A (en) |
| PE (1) | PE20190434A1 (en) |
| PH (1) | PH12018502104A1 (en) |
| PL (1) | PL3436051T3 (en) |
| PT (1) | PT3436051T (en) |
| RU (1) | RU2754467C2 (en) |
| SA (1) | SA518400146B1 (en) |
| SG (1) | SG11201808354PA (en) |
| WO (1) | WO2017173283A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017005834A (en) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease. |
| RU2749882C2 (en) | 2014-11-14 | 2021-06-18 | Вояджер Терапьютикс, Инк. | Modulating polynucleotides |
| EP3218484A4 (en) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| BR112018070256A2 (en) * | 2016-03-31 | 2019-01-29 | Spark Therapeutics Inc | fully scalable column-based raav manufacturing process |
| RU2758488C2 (en) | 2016-05-18 | 2021-10-28 | Вояджер Терапьютикс, Инк. | Modulating polynucleotides |
| JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| KR102669561B1 (en) * | 2017-06-30 | 2024-05-24 | 스파크 테라퓨틱스, 인코포레이티드 | AAV vector column purification method |
| IL314692A (en) * | 2017-11-08 | 2024-10-01 | Novartis Ag | Means and method for preparing viral vectors and uses of same |
| WO2019209632A1 (en) | 2018-04-24 | 2019-10-31 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
| JPWO2022045055A1 (en) * | 2020-08-24 | 2022-03-03 | ||
| WO2023077085A2 (en) * | 2021-10-29 | 2023-05-04 | Oxford Biomedica Solutions Llc | Methods and compositions for the purification of adeno-associated virus |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE69233013T2 (en) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | ADENOVIRUS MEDIATED GENTRANSFER INTO THE GASTROINTESTINAL TRACT |
| US5981716A (en) * | 1995-06-07 | 1999-11-09 | Gruppo Lepettit, S.P.A. | Process for the purification of proteins |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| DK1944362T3 (en) * | 1997-09-05 | 2016-01-25 | Genzyme Corp | Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer |
| US7125705B2 (en) | 2000-04-28 | 2006-10-24 | Genzyme Corporation | Polynucleotides for use in recombinant adeno-associated virus virion production |
| US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
| ATE490307T1 (en) * | 2003-05-21 | 2010-12-15 | Genzyme Corp | METHOD FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS WHICH ARE LARGELY FREE OF EMPTY CAPSIDS |
| ES2714007T3 (en) | 2007-04-09 | 2019-05-24 | Univ Florida | Compositions of rAAV vectors that have tyrosine modified capsid proteins and methods for their use |
| SG176283A1 (en) * | 2009-06-16 | 2012-01-30 | Genzyme Corp | Improved methods for purification of recombinant aav vectors |
| EP2325194A1 (en) * | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| AU2011209743B2 (en) | 2010-01-28 | 2016-03-10 | The Children's Hospital Of Philadelphia | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| JP2014528729A (en) | 2011-10-05 | 2014-10-30 | モルメド エスピーエー | Virus vector purification system |
| BR112018070256A2 (en) * | 2016-03-31 | 2019-01-29 | Spark Therapeutics Inc | fully scalable column-based raav manufacturing process |
-
2017
- 2017-03-31 BR BR112018070256A patent/BR112018070256A2/en unknown
- 2017-03-31 ES ES17776783T patent/ES2896080T3/en active Active
- 2017-03-31 SG SG11201808354PA patent/SG11201808354PA/en unknown
- 2017-03-31 DK DK17776783.7T patent/DK3436051T3/en active
- 2017-03-31 LT LTEPPCT/US2017/025396T patent/LT3436051T/en unknown
- 2017-03-31 CA CA3019133A patent/CA3019133A1/en active Pending
- 2017-03-31 PL PL17776783T patent/PL3436051T3/en unknown
- 2017-03-31 PT PT177767837T patent/PT3436051T/en unknown
- 2017-03-31 MY MYPI2018001663A patent/MY195391A/en unknown
- 2017-03-31 US US16/088,743 patent/US11702639B2/en active Active
- 2017-03-31 HU HUE17776783A patent/HUE056854T2/en unknown
- 2017-03-31 AU AU2017240721A patent/AU2017240721B2/en active Active
- 2017-03-31 JP JP2018550782A patent/JP7364306B2/en active Active
- 2017-03-31 KR KR1020187031464A patent/KR102405250B1/en active IP Right Grant
- 2017-03-31 CN CN201780022146.8A patent/CN109152821A/en active Pending
- 2017-03-31 EP EP17776783.7A patent/EP3436051B1/en active Active
- 2017-03-31 WO PCT/US2017/025396 patent/WO2017173283A1/en active Application Filing
- 2017-03-31 PE PE2018001938A patent/PE20190434A1/en unknown
- 2017-03-31 RU RU2018138164A patent/RU2754467C2/en active
-
2018
- 2018-09-26 IL IL261970A patent/IL261970A/en unknown
- 2018-09-27 CL CL2018002754A patent/CL2018002754A1/en unknown
- 2018-09-28 PH PH12018502104A patent/PH12018502104A1/en unknown
- 2018-09-30 SA SA518400146A patent/SA518400146B1/en unknown
- 2018-10-18 CO CONC2018/0011151A patent/CO2018011151A2/en unknown
-
2022
- 2022-06-07 JP JP2022092235A patent/JP2022120011A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018002754A1 (en) | 2019-02-01 |
| PL3436051T3 (en) | 2022-02-07 |
| EP3436051B1 (en) | 2021-07-28 |
| SA518400146B1 (en) | 2021-10-19 |
| IL261970A (en) | 2018-10-31 |
| RU2018138164A3 (en) | 2020-06-16 |
| US11702639B2 (en) | 2023-07-18 |
| JP2022120011A (en) | 2022-08-17 |
| BR112018070256A2 (en) | 2019-01-29 |
| JP2019509745A (en) | 2019-04-11 |
| RU2018138164A (en) | 2020-04-30 |
| JP7364306B2 (en) | 2023-10-18 |
| KR20190006951A (en) | 2019-01-21 |
| DK3436051T3 (en) | 2021-11-01 |
| HUE056854T2 (en) | 2022-03-28 |
| CA3019133A1 (en) | 2017-10-05 |
| AU2017240721A1 (en) | 2018-10-11 |
| CN109152821A (en) | 2019-01-04 |
| AU2017240721B2 (en) | 2023-10-12 |
| PE20190434A1 (en) | 2019-03-21 |
| WO2017173283A1 (en) | 2017-10-05 |
| KR102405250B1 (en) | 2022-06-02 |
| US20200299650A1 (en) | 2020-09-24 |
| PT3436051T (en) | 2021-11-02 |
| LT3436051T (en) | 2021-11-25 |
| ES2896080T3 (en) | 2022-02-23 |
| CO2018011151A2 (en) | 2019-04-30 |
| EP3436051A1 (en) | 2019-02-06 |
| RU2754467C2 (en) | 2021-09-02 |
| MY195391A (en) | 2023-01-18 |
| EP3436051A4 (en) | 2019-10-16 |
| PH12018502104A1 (en) | 2019-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808354PA (en) | Column-based fully scalable raav manufacturing process | |
| SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201804400SA (en) | Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use | |
| SG11201900366QA (en) | Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby | |
| SG11201808215SA (en) | Aluminum alloys having iron, silicon, vanadium and copper, and with a high volume of ceramic phase therein | |
| SG11201810834WA (en) | Hepatitis b antiviral agents | |
| SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
| SG11201804770QA (en) | Method and arrangement for recovery of salt | |
| SG11201811161YA (en) | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
| SG11201807885PA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases |